deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT00539929

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Proof of Principle, Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled, Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Sponsor: Eisai Inc.

Conditions Chronic Plaque Psoriasis
Interventions E6201 0.005% E6201 0.01% E6201 0.03% Placebo
Updated 7 times since 2017 Last updated: Feb 3, 2017 Started: Sep 30, 2007 Primary completion: Jun 30, 2008 Completion: Jul 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Plaque Psoriasis, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Inc.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Boise, United States , Carlstadt, United States , Champaign, United States , Clinton Township, United States , College Station, United States , Fridley, United States , Hot Springs, United States , Lynchburg, United States , Omaha, United States and 2 more locations